NYSE · ICUI
Healthcare · Medical - Instruments & Supplies
$175.10
Up+$0.00 (+0.00%)
Updated Aug 31, 2026, 9:13 AM
SID Score
6.1/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ICUI closed at $175.10 after 20 trading sessions, up 1.25% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $175.45 | $177.68 | $174.10 | $175.10 | 162.21K |
| Aug 27, 2026 | $177.49 | $179.07 | $174.88 | $175.10 | 263.69K |
| Aug 26, 2026 | $182.80 | $182.84 | $179.18 | $179.59 | 161.55K |
| Aug 25, 2026 | $182.53 | $183.245 | $180.65 | $182.24 | 130.35K |
| Aug 24, 2026 | $184.39 | $185.00 | $180.26 | $182.55 | 230.44K |
| Aug 21, 2026 | $183.05 | $183.9999 | $181.0701 | $182.84 | 182.32K |
| Aug 20, 2026 | $184.16 | $187.88 | $182.26 | $182.53 | 255.36K |
| Aug 19, 2026 | $185.82 | $189.295 | $185.25 | $187.26 | 235.04K |
| Aug 18, 2026 | $182.79 | $185.32 | $182.50 | $183.76 | 241.93K |
| Aug 17, 2026 | $182.70 | $185.20 | $181.93 | $182.51 | 291.92K |
| Aug 14, 2026 | $182.25 | $184.33 | $181.30 | $182.98 | 192.21K |
| Aug 13, 2026 | $180.22 | $183.37 | $178.72 | $183.11 | 186.25K |
| Aug 12, 2026 | $180.31 | $181.045 | $177.02 | $179.34 | 314.05K |
| Aug 11, 2026 | $182.42 | $185.30 | $181.62 | $182.08 | 250.41K |
| Aug 10, 2026 | $182.67 | $186.17 | $180.885 | $182.42 | 476.88K |
| Aug 7, 2026 | $182.35 | $192.85 | $180.88 | $184.56 | 931.26K |
| Aug 6, 2026 | $167.28 | $168.36 | $164.09 | $166.37 | 359.63K |
| Aug 5, 2026 | $171.96 | $172.02 | $166.22 | $166.40 | 325.68K |
| Aug 4, 2026 | $171.98 | $173.04 | $169.67 | $171.96 | 320.76K |
| Aug 3, 2026 | $171.73 | $176.27 | $170.625 | $172.94 | 579.12K |
The latest Smart Investors Daily articles mentioning ICUI.
ICUI research
Company profile and research snapshot.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Piper Sandler | Overweight | — |
| Aug 7, 2026 | BTIG | Buy | — |
| Aug 7, 2026 | Needham | Buy | — |
| Jul 21, 2026 | Keybanc | Overweight | — |
| Jun 15, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 14, 2026
Daniel Woolson, VP at ICU Medical (NASDAQ:ICUI), reported an insider sell on August 13, according to a new SEC filing. What Happened: After conducting a thorough analysis, Woolson sold 5,417 shares of ICU Medical. This
Benzinga · Aug 13, 2026
A substantial insider sell was reported on August 12, by Ben Sousa, Chief Information Officer at ICU Medical (NASDAQ:ICUI), based on the recent SEC filing. What Happened: After conducting a thorough analysis, Sousa sold
Benzinga · Aug 12, 2026
Disclosed on August 11, Christian Voigtlander, Chief Operating Officer at ICU Medical (NASDAQ:ICUI), executed a substantial insider sell as per the latest SEC filing. What Happened: According to a Form 4 filing with the
Benzinga · Aug 12, 2026
Elisha W Finney, Board Member at ICU Medical (NASDAQ:ICUI), disclosed an insider sell on August 11, according to a recent SEC filing. What Happened: According to a Form 4 filing with the U.S. Securities and Exchange
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ICUI.
